Retraction Note to: Cell Death & Disease
https://doi.org/10.1038/s41419-018-1139-z published online 27 October 2018
The Editors have retracted this article. After publication concerns were raised about two of the figures. Specifically:
-
In Figure 3B there appear to be areas of overlap and duplication
-
In Figure 6C the HE T1 and HE T2 panels appear to be the same
The Editors therefore no longer have confidence in the data presented. Wenda Zhang, Wenying Yu, Guiping Cai, Jiawen Zhu, Shanshan Li, Jianpeng Guo, Guoping Yin, Chen Chen and Lingyi Kong disagree with this retraction. Chao Zhang has not responded to any correspondence from the Editors or the Publisher about this retraction.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Edited by A. Stephanou
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhang, W., Yu, W., Cai, G. et al. Retraction Note to: A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy. Cell Death Dis 12, 522 (2021). https://doi.org/10.1038/s41419-021-03809-2
Published:
DOI: https://doi.org/10.1038/s41419-021-03809-2
This article is cited by
-
Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells
Scientific Reports (2023)
-
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
Journal of Hematology & Oncology (2022)
